CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
Multiple Myeloma
DRUG: CDC-501
Confirmed M-Protein Response During Single Agent CDC-501 Therapy, M-Protein response evaluated every 4 weeks through urine and serum electrophoresis., Response assessed every 4 weeks; up to 62 months
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.